Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of "Hold" from Analysts

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has received a consensus recommendation of "Hold" from the six research firms that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $50.00.

OMCL has been the subject of several recent research reports. Benchmark reiterated a "buy" rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Wells Fargo & Company cut their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Bank of America cut their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. Craig Hallum boosted their price objective on Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, JPMorgan Chase & Co. boosted their price objective on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research report on Thursday, November 21st.

Insider Transactions at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares of the company's stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.64% of the company's stock.

Hedge Funds Weigh In On Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its stake in Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company's stock worth $31,955,000 after buying an additional 3,570 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company's stock worth $50,071,000 after buying an additional 1,138,921 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in shares of Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company's stock valued at $49,742,000 after purchasing an additional 243,353 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Omnicell by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock valued at $48,176,000 after purchasing an additional 2,877 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. acquired a new position in shares of Omnicell in the 3rd quarter valued at $32,721,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Price Performance

OMCL stock traded up $0.55 during trading on Thursday, hitting $43.17. 245,440 shares of the company traded hands, compared to its average volume of 335,053. The stock's 50-day simple moving average is $44.71 and its 200 day simple moving average is $42.01. The company has a market cap of $2.00 billion, a PE ratio of -110.69, a P/E/G ratio of 29.93 and a beta of 0.78. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.